Search Within

Stephen D Nimer

  1. "Alison Gencarelli"
Formats
  1. Journal Article (2)
  2. Meeting Abstract (2)
Groups
  1. Center for Hematologic Malignancies (4)
  2. Department of Medicine (4)
  3. Hematologic Malignancies, Division of (4)
  4. Lymphoma (4)
  5. Nursing (4)
  6. Radiation Oncology, Department of (2)

More Groups

People
  1. Alison Gencarelli (4)
  2. Andrew Zelenetz (4)
  3. Craig Moskowitz (4)
  4. Carol Portlock (3)
  5. David Straus (3)
  6. Ariela Noy (2)

More People

Years
  1. 2007 (1)
  2. 2004 (1)
  3. 2001 (1)
  4. 1998 (1)
Publications
  1. Blood (3)
  2. Annals of Oncology (1)
Publishers
  1. American Society of Hematology (3)
  2. Oxford University Press (1)

Results (4)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Maintaining the dose intensity of ICE chemotherapy with a thrombopoietic agent, PEG-rHuMGDF, may confer a survival advantage in relapsed and refractory aggressive non-Hodgkin lymphoma
    Journal Article

    Moskowitz, C. H.; Hamlin, P. A.; Gabrilove, J.; Bertino, J. R.; Portlock, C. S.; Straus, D. J.; Gencarelli, A. N.; Nimer, S. D.; Zelenetz, A. D.
    Annals of Oncology (2007)

    Fulltext@MSK | Save
  • Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma
    Journal Article

    Kewalramani, T.; Zelenetz, A. D.; Nimer, S. D.; Portlock, C.; Straus, D.; Noy, A.; O'connor, O.; Filippa, D. A.; Teruya-Feldstein, J.; Gencarelli, A.; more...
    Blood (2004)

    Fulltext@MSK | Save
  • Rituximab significantly increases the complete response rate in patients with relapsed or primary refractory DLBCL receiving ICE as second-line therapy (SLT)
    Meeting Abstract

    Kewalramani, T.; Zelenetz, A.; Bertino, J.; Donnelly, G.; Hedrick, E.; Noy, A.; O'connor, O.; Portlock, C.; Straus, D.; Yahalom, J.; more...
    Blood (2001)

    Fulltext@MSK | Save
  • A randmized phase II study of peripheral blood progenitor cell (PBPC) mobilization using chemotherapy followed by G-CSF with or without stem cell factor (SCF) in patients with Hodgkin's disease (HD), non-Hodgkin's lymphoma (NHL), and multiple myeloma (MM)
    Meeting Abstract

    Hedrick, E. E.; Nimer, S. D.; Zelenetz, A. D.; Gabrilove, J.; Wyres, M.; Gencarelli, A.; Karp, P.; Moskowitz, C. H.
    Blood (1998)

    Fulltext@MSK | Save